Vacino Biotech, founded by biotech veteran Chia-Ming Chang, is taking the spotlight with their cutting-edge technologies! With over 17 years of experience at DCB, Chang has led his team at Vacino to focus on broad-spectrum vaccines, Alzheimer's miRNA therapies, and innovative brain-penetrating technologies. 
 
Their Oral COVID-19 Vaccine is designed for broad efficacy and is set to enter clinical trials next year! But that’s not all—Vacino's miRNA therapy for Alzheimer’s, capable of crossing the Blood-Brain Barrier (BBB), is already gaining attention from global pharma giant AbbVie, with exciting partnership talks underway! 
 
With their breakthrough Vacino-BT platform and the success of Nobel-winning miRNA research, Vacino is positioning itself to lead the next wave of nucleic acid therapies in the coming years! 
 
They were also selected as a finalist for the 2024 Global Vaccine Conference Best Technology Platform Award! 
 
Stay tuned for more innovations and follow #Globalbio for the latest updates in biotech and medical breakthroughs! 
 
#AlzheimersTreatment #miRNA #BiotechInnovation #OralVaccine #BrainBarrier #NucleicAcidTherapy #VacinoBT #Globalbio #FutureOfMedicine